Veracyte (VCYT) announced it has met its targeted enrollment for the NIGHTINGALE trial, which aims to evaluate the clinical utility of its Percepta Nasal Swab test.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCYT:
- Veracyte management to meet with Craig-Hallum
- Cautious Outlook on Veracyte: Sell Rating Amid Market Uncertainties and Valuation Concerns
- Veracyte price target lowered to $28 from $29 at Morgan Stanley
- Veracyte’s Strong Clinical Evidence and Market Growth Justify Buy Rating
- Veracyte Inc’s Earnings Call Highlights Robust Growth and Strategic Milestones